Heart Failure pp 261-264 | Cite as

Cardiac Allograft Vasculopathy

  • Finn GustafssonEmail author
Part of the Cardiovascular Medicine book series (CVM)


Cardiac allograft vasculopathy (CAV) – formerly termed chronic rejection – was described already in 1969, 2 years after the first heart transplant [1]. Soon after the phenomenon was described in details on cadaveric hearts as an obliterative intimal proliferation of the coronary arteries [2]. It became clear that CAV is a disease of the coronary circulation of transplanted hearts distinct from conventional arteriosclerosis. It is a very important complication after heart transplantation as it affects 30–40% of recipients after 5 years and since it is the dominating cause of graft failure and a common cause of death late after transplant [3]. CAV involves not only epicardial arteries but also intramyocardial small arteries and arterioles as well as the cardiac venous vessels (Fig. 21.1). Rapidly, the diagnosis moved from being pathologic-anatomic to become radiologic as coronary angiography was introduced as a routine examination in heart transplant recipients. Typically CAV presents on angiography as diffuse coronary disease with distal arterial obliteration and often also significant proximal stenosis (Fig. 21.2). Further insight to the natural history of CAV was obtained from intravascular ultrasound (IVUS) studies, which have been used primarily for research. Recent developments include use of optical coherence tomography, MRI and CT angiography.


  1. 1.
    Thompson JG. Atheroma in a transplanted heart. Lancet. 1969;2(7633):1297.CrossRefGoogle Scholar
  2. 2.
    Bieber CP, Stinson EB, Shumway NE, Payne R, Kosek J. Cardiac transplantation in man. VII. Cardiac allograft pathology. Circulation. 1970;41(5):753–72.CrossRefGoogle Scholar
  3. 3.
    Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb S, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-second official adult heart transplantation report—2015; focus theme: early graft failure. J Heart Lung Transplant. 2015;34(10):1244–54.CrossRefGoogle Scholar
  4. 4.
    Costanzo MR, Naftel DC, Pritzker MR, Heilman JK III, Boehmer JP, Brozena SC, et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac transplant research database. J Heart Lung Transplant. 1998;17(8):744–53.PubMedGoogle Scholar
  5. 5.
    Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, et al. The registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report—2012. J Heart Lung Transplant. 2012;31(10):1052–64.CrossRefGoogle Scholar
  6. 6.
    Nath DS, Angaswamy N, Basha HI, Phelan D, Moazami N, Ewald GA, et al. Donor-specific antibodies to human leukocyte antigens are associated with and precede antibodies to major histocompatibility complex class I-related chain a in antibody-mediated rejection and cardiac allograft vasculopathy after human cardiac transplantation. Hum Immunol. 2010;71(12):1191–6.CrossRefGoogle Scholar
  7. 7.
    Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E, et al. Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant. 2014 Aug;14(8):1828–38.CrossRefGoogle Scholar
  8. 8.
    Delgado JF, Reyne AG, de Dios S, Lopez-Medrano F, Jurado A, Juan RS, et al. Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation. J Heart Lung Transplant. 2015;34(8):1112–9.CrossRefGoogle Scholar
  9. 9.
    Potena L, Grigioni F, Magnani G, Lazzarotto T, Musuraca AC, Ortolani P, et al. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant. 2009;28(5):461–7.CrossRefGoogle Scholar
  10. 10.
    Valantine H, Rickenbacker P, Kemna M, Hunt S, Chen YD, Reaven G, et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study. Circulation. 2001;103(17):2144–52.CrossRefGoogle Scholar
  11. 11.
    Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333(10):621–7.CrossRefGoogle Scholar
  12. 12.
    Arora S, Aukrust P, Andreassen A, Simonsen S, Gude E, Grov I, et al. The prognostic importance of modifiable risk factors after heart transplantation. Am Heart J. 2009;158(3):431–6.CrossRefGoogle Scholar
  13. 13.
    Mehra MR, Crespo-Leiro MG, Dipchand A, Ensminger SM, Hiemann NE, Kobashigawa JA, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant. 2010;29(7):717–27.CrossRefGoogle Scholar
  14. 14.
    Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29(8):914–56.CrossRefGoogle Scholar
  15. 15.
    Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation. 1997;96(5):1398–402.CrossRefGoogle Scholar
  16. 16.
    Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-Von Kaeppler HA, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349(9):847–58.CrossRefGoogle Scholar
  17. 17.
    Eisen HJ, Kobashigawa J, Starling RC, Pauly DF, Kfoury A, Ross H, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant. 2013;13(5):1203–16.CrossRefGoogle Scholar
  18. 18.
    Arora S, Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Botker HE, et al. The effect of Everolimus initiation and Calcineurin inhibitor elimination on cardiac allograft vasculopathy in De novo recipients: one-year results of a Scandinavian randomized trial. Am J Transplant. 2015;15(7):1967–75.CrossRefGoogle Scholar
  19. 19.
    Ruygrok PN, Webber B, Faddy S, Muller DW, Keogh A. Angiographic regression of cardiac allograft vasculopathy after introducing sirolimus immunosuppression. J Heart Lung Transplant. 2003;22(11):1276–9.CrossRefGoogle Scholar
  20. 20.
    Masetti M, Potena L, Nardozza M, Prestinenzi P, Taglieri N, Saia F, et al. Differential effect of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice. Am J Transplant. 2013;13(5):1217–26.CrossRefGoogle Scholar
  21. 21.
    Goldraich LA, Stehlik J, Kucheryavaya AY, Edwards LB, Ross HJ. Retransplant and medical therapy for cardiac allograft vasculopathy: International Society for Heart and Lung Transplantation registry analysis. Am J Transplant. 2016;16(1):301–9.CrossRefGoogle Scholar
  22. 22.
    Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report--2014; focus theme: retransplantation. J Heart Lung Transplant. 2014;33(10):996–1008.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.RigshospitaletCopenhagenDenmark

Personalised recommendations